

Oridonin (Luo, 2019)



Background

- · A diterpenoid that is biosynthetically related to ent-kaurene
- · Widely investigated in preclinical and clinical settings
- The major active component in Rabdosia rubescens, an over-the-counter anti-inflammatory medicine available in China
- Many semi-synthetic efforts, one of which entered phase I clinical trials for treatment of leukemia
- Potential also for application in neuroprotection and treatment of neurodegenerative diseases
- Mechanism of action studies indicate interaction with the $\alpha-\text{methylene}$ cyclopentenone motif





Western Fragment Synthesis

Eastern Fragment Synthesis

Luo, T. et al. J. Am. Chem. Soc. 2019, 141, 20048-20052



Oridonin (Luo, 2019)



Luo, T. et al. J. Am. Chem. Soc. 2019, 141, 20048-20052

(-)-oridonin





